Editorial
12 July 2023
The biological dupilumab leads to fewer exacerbations, better lung function, better quality of life and less severe respiratory symptoms in COPD patients with type 2 inflammation. This is the conclusion of a phase 3 clinical study that European and American researchers published in May 2023 in The New England Journal of Medicine.
There are indications of type 2 inflammation in 20 to 40% of COPD patients. This is associated with an increased risk of exacerbations. Cytokines that play an important role in type-2 inflammation are IL-4, IL-5 and IL-13. There are several biologicals that target these cytokines and their receptors. These are prescribed, among other things, for patients with severe asthma and/or severe chronic rhinosinusitis with nasal polyps (CRSwNP).
The current study investigates the efficacy and safety of the biological dupilumab (anti-IL4R/anti-IL13R) in patients with COPD who have evidence of type 2 inflammation, despite using triple inhalation therapy.
“The primary endpoint of the study was the number of moderate to severe COPD exacerbations per year”
Phase 3 study
The researchers conducted a phase 3, double-blind, randomized, placebo-controlled clinical trial (the BOREAS trial; NCT03930732). Participants consisted of COPD patients who had a blood eosinophilic granulocyte concentration of at least 300 cells per microliter and who had at least one
Read more about:
2023-07-12 15:32:36
#COPD #exacerbations #due #biological #dupilumab #DOQ
